---
title: "Fortrea Holdings Inc. (FTRE.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/FTRE.US.md"
symbol: "FTRE.US"
name: "Fortrea Holdings Inc."
industry: "Life Sciences Tools and Services"
---

# Fortrea Holdings Inc. (FTRE.US)

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Location | US Market |
| Website | [www.fortrea.com](https://www.fortrea.com) |

## Company Profile

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical services that provides development and consulting services to clinical pha...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-22T04:30:14.000Z

**Overall: D (0.65)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 45 / 62 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1.88% |  |
| Net Profit YoY | -215.38% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.75 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1.02B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 2.76B |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -98.13% | E |
| Profit Margin | -36.77% | E |
| Gross Margin | 17.50% | D |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1.88% | C |
| Net Profit YoY | -215.38% | E |
| Total Assets YoY | -25.15% | E |
| Net Assets YoY | -61.63% | E |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -271.94% | D |
| OCF YoY | 1.88% | C |

#### Operating Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.86 | B |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 78.82% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Fortrea Holdings Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-98.13%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-36.77%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "17.50%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1.88%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-215.38%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-25.15%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-61.63%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-271.94%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "1.88%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "B",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.86",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "78.82%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ChromaDex (US.CDXC) | A | A | A | B | B | A |
| 02 | Agilent Tech (US.A) | A | C | B | C | C | B |
| 03 | Waters (US.WAT) | A | B | B | C | C | B |
| 04 | WuXi Biologics (US.WXXWY) | B | B | D | A | B | B |
| 05 | West Pharmaceutical (US.WST) | B | B | B | B | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.00 | 30/59 | - | - | - |
| PB | 1.75 | 23/59 | 2.02 | 1.29 | 0.52 |
| PS (TTM) | 0.37 | 3/59 | 0.44 | 0.32 | 0.18 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-14T05:00:00.000Z

Total Analysts: **12**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 4 | 33% |
| Overweight | 1 | 8% |
| Hold | 6 | 50% |
| Underweight | 1 | 8% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 11.00 |
| Highest Target | 25.00 |
| Lowest Target | 8.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/FTRE.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/FTRE.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/FTRE.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.